Page last updated: 2024-11-06

abnormal cannabidiol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID89949
CHEMBL ID499876
CHEBI ID197013
SCHEMBL ID10296688
MeSH IDM0457834

Synonyms (32)

Synonym
(e)-(-)-4-p-mentha-1,8-dien-3-yl-5-pentylresorcinol
resorcinol, 4-p-mentha-1,8-dien-3-yl-5-pentyl-, (-)-(e)-
22972-55-0
CHEMBL499876 ,
CHEBI:197013
cay10429
4-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
4-((1r,6r)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol
unii-t4wf2d7yph
t4wf2d7yph ,
abnormal cannabidiol
4-[(1r,6r)-3-methyl-6-prop-1-en-2-yl-1-cyclohex-2-enyl]-5-pentylbenzene-1,3-diol
gtpl5526
4-[(1r,6r)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol
abnormal-cannabidiol
SCHEMBL10296688
4-((1r,6r)-6-isopropenyl-3-methyl-cyclohex-2-enyl)-5-pentyl-benzene-1,3-diol
AKOS024456514
HMS3649P13
1,3-benzenediol, 4-[3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-, trans-(-)-
J-014925
hvd ,
(1'r,2'r)-5'-methyl-6-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydro[1,1'-biphenyl]-2,4-diol
Q27074295
SR-01000946689-1
sr-01000946689
nsc792738
nsc-792738
1,3-benzenediol, 4-[(1r,6r)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-
DTXSID10945675
bdbm50552130
E98778
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monoterpenoidAny terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
N-arachidonyl glycine receptorHomo sapiens (human)IC50 (µMol)10.00005.99005.99005.9900AID1725631
G-protein coupled receptor 55Homo sapiens (human)IC50 (µMol)10.00000.64000.64000.6400AID1725635
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
N-arachidonyl glycine receptorHomo sapiens (human)EC50 (µMol)10.00000.02001.55804.6100AID1725628
G-protein coupled receptor 55Homo sapiens (human)EC50 (µMol)5.00100.00200.66622.0100AID1692629; AID1725633
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
CD8-positive, alpha-beta intraepithelial T cell differentiationN-arachidonyl glycine receptorHomo sapiens (human)
CD8-positive, gamma-delta intraepithelial T cell differentiationN-arachidonyl glycine receptorHomo sapiens (human)
negative regulation of leukocyte chemotaxisN-arachidonyl glycine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayN-arachidonyl glycine receptorHomo sapiens (human)
negative regulation of tumor necrosis factor productionN-arachidonyl glycine receptorHomo sapiens (human)
positive regulation of Rho protein signal transductionN-arachidonyl glycine receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayN-arachidonyl glycine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled receptor 55Homo sapiens (human)
activation of phospholipase C activityG-protein coupled receptor 55Homo sapiens (human)
positive regulation of Rho protein signal transductionG-protein coupled receptor 55Homo sapiens (human)
cannabinoid signaling pathwayG-protein coupled receptor 55Homo sapiens (human)
bone resorptionG-protein coupled receptor 55Homo sapiens (human)
negative regulation of osteoclast differentiationG-protein coupled receptor 55Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeG-protein coupled receptor 55Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayG-protein coupled receptor 55Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityN-arachidonyl glycine receptorHomo sapiens (human)
G protein-coupled receptor activityG-protein coupled receptor 55Homo sapiens (human)
cannabinoid receptor activityG-protein coupled receptor 55Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneN-arachidonyl glycine receptorHomo sapiens (human)
membraneN-arachidonyl glycine receptorHomo sapiens (human)
cytoplasmic vesicle membraneN-arachidonyl glycine receptorHomo sapiens (human)
plasma membraneN-arachidonyl glycine receptorHomo sapiens (human)
plasma membraneG-protein coupled receptor 55Homo sapiens (human)
plasma membraneG-protein coupled receptor 55Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID1725632Antagonist activity at Prolink1-tagged human GPR18 receptor expressed in CHO cells assessed as inhibition of THC-induced beta arrestin recruitment at 10 uM after 90 mins by beta-galactosidase based topcount luminescence analysis relative to control2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Discovery of Tricyclic Xanthines as Agonists of the Cannabinoid-Activated Orphan G-Protein-Coupled Receptor GPR18.
AID362542Antibacterial activity against macrolide-resistant Staphylococcus aureus RN4220 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID1725629Agonist activity at Prolink1-tagged human GPR18 receptor expressed in CHO cells assessed as induction of beta-arrestin recruitment at 10 uM after 90 mins by beta-galactosidase based topcount luminescence analysis relative to control2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Discovery of Tricyclic Xanthines as Agonists of the Cannabinoid-Activated Orphan G-Protein-Coupled Receptor GPR18.
AID1725633Agonist activity at Prolink1-tagged human GPR55 receptor expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase based topcount luminescence analysis2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Discovery of Tricyclic Xanthines as Agonists of the Cannabinoid-Activated Orphan G-Protein-Coupled Receptor GPR18.
AID1725634Agonist activity at Prolink1-tagged human GPR55 receptor expressed in CHO cells assessed as induction of beta-arrestin recruitment at 10 uM after 90 mins by beta-galactosidase based topcount luminescence analysis relative to control2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Discovery of Tricyclic Xanthines as Agonists of the Cannabinoid-Activated Orphan G-Protein-Coupled Receptor GPR18.
AID362546Antibacterial activity against epidemic methicillin-resistant Staphylococcus aureus 16 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID1725628Agonist activity at Prolink1-tagged human GPR18 receptor expressed in CHO cells assessed as induction of beta-arrestin recruitment after 90 mins by beta-galactosidase based topcount luminescence analysis2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Discovery of Tricyclic Xanthines as Agonists of the Cannabinoid-Activated Orphan G-Protein-Coupled Receptor GPR18.
AID1692629Activation of recombinant human GPR55 expressed in HEK293 cells assessed as increase in [35S]-GTPgammaS stimulation incubated for 60 min by scintillation counting method2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
The Essential Medicinal Chemistry of Cannabidiol (CBD).
AID362544Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 25923 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID1725635Antagonist activity at Prolink1-tagged human GPR55 receptor expressed in CHO cells assessed as inhibition of lysophosphatidylinositol-induced beta arrestin recruitment after 90 mins by beta-galactosidase based topcount luminescence analysis2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Discovery of Tricyclic Xanthines as Agonists of the Cannabinoid-Activated Orphan G-Protein-Coupled Receptor GPR18.
AID1725636Antagonist activity at Prolink1-tagged human GPR55 receptor expressed in CHO cells assessed as inhibition of lysophosphatidylinositol-induced beta arrestin recruitment at 10 uM after 90 mins by beta-galactosidase based topcount luminescence analysis relat2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Discovery of Tricyclic Xanthines as Agonists of the Cannabinoid-Activated Orphan G-Protein-Coupled Receptor GPR18.
AID362545Antibacterial activity against epidemic methicillin-resistant Staphylococcus aureus 15 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID362541Antibacterial activity against methicillin-resistant Staphylococcus aureus SA1199B after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID362543Antibacterial activity against tetracycline-resistant Staphylococcus aureus XU212 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID1725631Antagonist activity at Prolink1-tagged human GPR18 receptor expressed in CHO cells assessed as inhibition of THC-induced beta arrestin recruitment after 90 mins by beta-galactosidase based topcount luminescence analysis2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Discovery of Tricyclic Xanthines as Agonists of the Cannabinoid-Activated Orphan G-Protein-Coupled Receptor GPR18.
AID1345070Human GPR55 (GPR18, GPR55 and GPR119)2007British journal of pharmacology, Dec, Volume: 152, Issue:7
The orphan receptor GPR55 is a novel cannabinoid receptor.
AID1346814Human GPR18 (GPR18, GPR55 and GPR119)2012British journal of pharmacology, Apr, Volume: 165, Issue:8
Δ(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells.
AID1345070Human GPR55 (GPR18, GPR55 and GPR119)2007British journal of pharmacology, Nov, Volume: 152, Issue:5
The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's1 (16.67)24.3611
2020's2 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.90 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]